Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

83
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
83
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

106
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
106
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

96
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
96
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

83
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
83
Liver Regeneration01:24

Liver Regeneration

3.9K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.9K
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

816
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
816

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Screening the Tox21 Compound Library for Chemicals That Stimulate the Adrenergic β1 Receptor.

Chemical research in toxicology·2026
Same author

Expanded Tox21 Biological Assay Panel for the Prediction of Drug-Induced Liver Injury and Cardiotoxicity.

Environmental health perspectives·2026
Same author

Modeling hERG Channel Liability: From Structural Insight to Highly Accurate Qualitative and Quantitative Models.

Journal of chemical information and modeling·2026
Same author

Analysis of in vitro profiling data of cosmetic ingredients within the Tox21 10K compound library for bioactivity and potential toxicity.

BMC pharmacology & toxicology·2026
Same author

Deciphering small sequence differences in T cell receptor-antigen pairing.

Nature communications·2026
Same author

Leveraging machine learning for selective cannabinoid ligand discovery: methods, challenges, and opportunities.

Expert opinion on drug discovery·2026

Related Experiment Video

Updated: Nov 24, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.0K

Deep Graph Learning with Property Augmentation for Predicting Drug-Induced Liver Injury.

Hehuan Ma1, Weizhi An1, Yuhong Wang2

  • 1Department of Computer Science, University of Texas at Arlington, Arlington, Texas 76013, United States.

Chemical Research in Toxicology
|December 21, 2020
PubMed
Summary

Predicting drug-induced liver injury (DILI) is vital for drug development. Our novel computational method enhances DILI prediction accuracy, even with limited data, by using property augmentation for drug candidates.

More Related Videos

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.5K
A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

1.9K

Related Experiment Videos

Last Updated: Nov 24, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.0K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.5K
A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

1.9K

Area of Science:

  • Computational chemistry
  • Pharmacology
  • Toxicology

Background:

  • Drug-induced liver injury (DILI) is a critical safety concern in drug development.
  • Accurate DILI prediction is challenging due to complex testing and limited annotated data.
  • Early-stage in silico screening can reduce drug development costs by identifying high-risk candidates.

Purpose of the Study:

  • To develop an accurate computational method for predicting DILI properties.
  • To address the challenge of limited annotated data for DILI prediction models.
  • To improve the efficiency of early-stage drug discovery by filtering potential DILI-causing drug candidates.

Main Methods:

  • Application of traditional machine learning and graph-based deep learning techniques.
  • Development of a property augmentation strategy to overcome data scarcity.
  • Extensive experimental validation using various cross-validation strategies (random, leave-one-out, scaffold splitting).

Main Results:

  • The proposed method significantly outperforms existing baseline models for DILI prediction.
  • Achieved high accuracy rates: 81.4% (random splitting), 78.7% (leave-one-out), and 76.5% (scaffold splitting).
  • Property augmentation effectively mitigated the data scarcity issue for deep learning models.

Conclusions:

  • The developed computational approach offers a robust solution for predicting DILI.
  • This method can aid in early-stage drug discovery by effectively filtering drug candidates with high DILI risk.
  • The property augmentation strategy is a valuable technique for improving predictive model performance with limited datasets.